Progress of maintenance therapy with molecular targeted drugs for acute myeloid leukemia after transplantation

VernacularTitle:急性髓系白血病移植后分子靶向药物维持治疗的研究进展
Author: Yunfei GAO ¹ ; Xin ZHAO ; Xiaoliang LIU
Author Information

1. 吉林大学第一医院血液科，长春　130021
Keywords: Leukemia, myeloid, acute; Molecular targeted therapy; Hematopoietic stem cell transplantation; Maintenance therapy
From: Journal of Leukemia & Lymphoma 2025;34(5):317-320
CountryChina
Language:Chinese
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for patients with intermediate-high risk and relapsed/refractory acute myeloid leukemia (AML). Relapse remains the primary factor affecting the prognosis of patients after transplantation, with only a small number of patients achieving long-term survival after conventional salvage therapy. Molecular targeted drugs, as a new intervention measure, can significantly reduce the recurrence rate of AML after transplantation, without a significant increase in treatment-related adverse reactions. This article primarily focuses on the targeted drugs that are either in clinical use or in clinical trials, and reviews their role in maintenance therapy for AML after transplantation.